Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 6Gastrointestinal 4CNS 3Breast 3Plasma cell 2Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1Gynecologic 1

Conditions

Multiple Myeloma 2Recurrence 1

Interventions

Dexamethasone 479Lenalidomide 297Cyclophosphamide 271Bortezomib 267Melphalan 212Calcium Dobesilate 189fludarabine phosphate 121daratumumab 121Peripheral Blood Stem Cell Transplantation 101fludarabine 99carfilzomib 98Thalidomide 94pomalidomide 92Filgrastim 92Whole-Body Irradiation 88Mycophenolic Acid 88Busulfan 80Tacrolimus 75Granulocyte Colony-Stimulating Factor 72dexamethasone acetate 65ixazomib 62Cyclosporine 59dexamethasone 21-phosphate 56Antilymphocyte Serum 51auricularum 50isatuximab 44Radiotherapy 41Etoposide 40Stem Cell Transplantation 39Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Antibodies, Monoclonal × Plasma cell × Clear all
NCT07051850 2025-07-15

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

Seoul St. Mary's Hospital

Recruiting
174 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT03942224 2024-06-21

DeRIVE

Emory University

Phase 2 Active not recruiting
49 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡